Polarean Imaging Share Discussion Threads

[john henry] 19/1/2024 12:57

Excellent find epic ??

[epicsurf] 19/1/2024 11:26

New research sets to improve detection of high blood pressure in the lungs using advanced imaging tools
A new study at the University of Sheffield to enable quick and more accurate diagnosis of pulmonary arterial hypertension in patients with systemic sclerosis has received a £200,000 grant from Heart Research UK.


A new University of Sheffield study awarded £200,000 grant will enable quick and more accurate diagnosis of pulmonary arterial hypertension in patients with systemic sclerosis
Quicker and more accurate diagnosis will reduce the emotional and physical impact of the disease on patients
Around 10 per cent of patients with systemic sclerosis develop pulmonary arterial hypertension
The study will use innovative hyperpolarised imaging to provide detailed pictures of the transport of oxygen into the lungs
A new study at the University of Sheffield to enable quick and more accurate diagnosis of pulmonary arterial hypertension in patients with systemic sclerosis has received a £200,000 grant from Heart Research UK.

The project will use cutting-edge imaging methods to improve the identification of pulmonary arterial hypertension (PAH) in patients with systemic sclerosis (SSc) which will potentially enable quicker and more accurate diagnosis and reduce the emotional and physical impact of the disease on patients.

Systemic sclerosis is a disease of blood vessels, skin and other organs. Around 10 per cent of patients with systemic sclerosis develop pulmonary arterial hypertension, a problem with the blood vessels in the lungs that can ultimately lead to heart failure and death.

Around half of SSc patients diagnosed with PAH will die within three years, meaning better detection methods are needed to improve early diagnosis and quality of life.

The new research project is part of the National Institute for Health and Care Research (NIHR) Sheffield Biomedical Research Centre and is led by Dr Roger Thompson who seeks to use innovative hyperpolarised imaging.

Patients will undergo MRI scans while breathing a special ‘hyperpolarised’ gas that provides detailed pictures of the transport of oxygen into the lungs from the air and can measure blood flow in the lungs.

Dr Roger Thompson, said: “Our goal is to provide a quicker, more accurate diagnosis of pulmonary hypertension in patients with connective tissue diseases such as systemic sclerosis. By using advanced MRI scanning techniques, in which patients inhale a ‘hyperpolarised' gas, we hope to improve early detection of pulmonary hypertension and how we monitor response to treatment.

“This work aims to reduce the emotional and physical toll of the disease by providing the potential for earlier and more effective treatment strategies.”

The project will involve two groups, one set of patients with SSc who have developed PAH and the other who have not yet developed PAH. Patients will have MRI scans, and some will have repeat tests after six months to assess the disease progression.

Professor Wild, a co-investigator on the research project, said: “Exploring the sensitivity of our Sheffield-made hyperpolarised xenon gas MR imaging methods to the effects of connective tissue disease on gas exchange in the lungs, in this group of patients with pulmonary hypertension, is of great interest.

“Our group have developed and pioneered this technology over the years in Sheffield in collaboration with our clinical colleagues in the NHS at the Sheffield Pulmonary Vascular Disease Unit and this collaboration is vital in translating these methods for patient benefit.”

It is also hoped that this will allow for better monitoring of PAH and how it responds to drug therapy in different patients, providing insight into how best to treat the condition.

Kate Bratt-Farrar, Chief Executive at Heart Research UK, said: “We are delighted to be able to award one of our Novel and Emerging Technologies grants to Dr Thompson and his team.

This ground-breaking research will hopefully improve the identification of pulmonary arterial hypertension in patients with systemic sclerosis.

“The results from this study will hopefully improve patient quality of life whilst hopefully leading to the discovery of a new treatment that targets blood vessel damage.”

[nigelpm] 18/1/2024 09:27

This is where you let yourself down Moon - JH's post was perfectly reasonable and sensible. Different views are good.

[john henry] 18/1/2024 09:25

Nukum takeover Really Moontheloon checkout Nukums revenue for last year.

[moontheloon] 18/1/2024 08:58

Lol you won't get much cheaper jh. Nothing changed since yesterday. I'd rather trust jakos confidence than you're random attempts to make it sound panic stations. Anything but . But we've covered this haven't we ... I personally think nukem now strongest contender for full acquisition.

[john henry] 18/1/2024 08:18

Problem here is that the company is not delivering on key milestones as the clock clicks down on funding requirements.

[pj84] 17/1/2024 22:24

Possibly, but it seems he may already have an idea that they are keen to invest more and as a supportive strategic investor, it might not be dilutive.

[nigelpm] 17/1/2024 18:09

"No doubt they will invest in our next round"

A slip up??

[nigelpm] 17/1/2024 18:08

Interesting bit on Amati from there - suggests might be done for now.

[pj84] 15/1/2024 16:24

They must expect the market to grow and aren't interested in just supplying the xenon but want to benefit from the lung imaging as well.

"Hyperpolarization of Xenon-129 is a revolutionary new
diagnostic imaging tool for the magnetic resonance
imaging (MRI) technology.

Hyperpolarized Xenon-129 makes it possible to
capturing high-resolution, 3D images of the lung using
a conventional MRI scanner.

Due to the varying solubility of Xenon in different
environment, it is additionally possible to illuminate
organ functions and tissue characteristics in a total
way.

Our Xenon-129 gas mixtures are optimized for the
use in polarizers made by Polarean Inc.*

[moontheloon] 15/1/2024 16:01

Polarean Imaging PLC - London-based developer of medical imaging devices providing magnetic resonance imaging of the lungs - Strategic partner NUKEM Isotopes GmbH buys 9.5 million Polarean shares from Amati Global Investors Ltd, raising its stake to 10.5% from 6.1%. Alzenau, Germany-based NUKEM is a trading company in stable isotopes and noble gases. Amati retains a 4.6% stake in Polarean, down from its last reported level of 9.8%. The shares purchased by NUKEM are worth GBP725,800 at Polarean's current market price.Current stock price: 7.64 pence, up 1.8%

[teamrilex] 15/1/2024 09:16

Translated roughly as… “we’re not much cop at this RNS mullarkey, so, just to clarify… the note we put out on Friday is meant to be positive news… please, please, please interpret it as such!” 😉😂

[moontheloon] 15/1/2024 08:39

That faith. Oversold under valued status and no massive selling pressure should see us back well into double figures.

[moontheloon] 15/1/2024 08:37

It maybe if they continue to add %. And I think what it says between the lines is enormous for the company

[nigelpm] 15/1/2024 08:04

The reason is obvious - Nukem asked/gave them permission to make the comment.

The question however is why RNS it. It's not material to the business.

[fred177] 15/1/2024 08:00

seems to be saying frig Amati real people in the industry have faith

[john henry] 15/1/2024 08:00

My guess for the RNS is that Nukem is and is seen as a strategic partner.
Amati was until recently a supportive significant investor.
Saying that Amati still own 4.4%

[nigelpm] 15/1/2024 07:51

Snap. Only referring to the buy side. Odd

[purchaseatthetop] 15/1/2024 07:34

That is the weirdest RNS I have ever seen!

[nigelpm] 15/1/2024 07:14

That's a bizarre RNS.. can't recall similar

[moontheloon] 15/1/2024 07:07

The support from nukem is more important a sign than amati holding

[nigelpm] 12/1/2024 19:54

hxxps://www.linkedin.com/feed/update/urn:li:activity:7151606881831047168/

Happy 2024! Just returned from a highly productive week at the #jpm2024 Healthcare Conference, reconnecting with potential and existing #medtech and #pharma partners, investors, bankers, and friends. The new year brings renewed energy to revolutionize pulmonary medicine with our innovative Polarean functional lung platform.

[nigelpm] 12/1/2024 19:41

Quite - but put that behind us the question now is simple. Does the current valuation reflect all future prospects of POLX?

[goldbutler] 12/1/2024 19:26

polx share p7.5p

It is indeed a concern that Amati see no future in being a shareholder.

The Board of Polarean have had 3 years and 27 million to commercialise and they
have now lost a large shareholder. WHY?

Are they too to be called "NOBODY" by some on this board.

These shareholders funded the company with the working capital to get to this fda approved stage and the utter shambles from BOD since this time last year is a disgrace. The lack of communication is appalling - twice a year and a AGM in the USA.

The new CEO track record is appalling unlike the CEO appointed to destiny Pharma

The share prices reflect this.

The behaviour of the Patel director and shareholder on SHANTA Gold and an offer for that company should give cause for concern to shareholders of Polarean.
Shareholders at Shanta are outraged. Aim and self serving group of directors.

Shareholders own the company not the board of directors

Will Shanta Gold directors behaviour happen at Polarean.
#